Oncotelic announces JV agreement signing, press release and 8-K forthcoming

Oncotelic Therapeutics, Inc.

Presented at MedInvest Pharmaceutical and Biotechnology Investor Conference on March 31, 2022.
Company stated a joint venture agreement is being signed; further disclosure via press release and 8-K.
No details on JV partner, terms, or timeline provided in the filing.
Presentation and recording available on company website and YouTube channel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.